Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | CCR5 | P51681 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26413555 | 0.86 | AGER (0.45) | KMT2AF2MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL28034923 | 0.84 | HSD11B1 (0.56) | HSD11B1CCR5KMT2AF2MMP13 | |
| SCHEMBL26413513 | 0.80 | HSD11B1 (0.44) | HSD11B1CCR5KMT2AF2MMP13 | |
| SCHEMBL26413565 | 0.77 | F2 (0.43) | HSD11B1CCR5KMT2AF2MMP13 | |
| SCHEMBL28610867 | 0.76 | ESR1 (0.46) | HSD11B1CCR5KMT2AF2MMP13 | |
| SCHEMBL7815449 | 0.75 | PTGES (0.43) | HSD11B1CCR5KMT2AESR2NR1H3 | |
| SCHEMBL11514144 | 0.74 | F2 (0.41) | HSD11B1CCR5KMT2AF2MMP13 | |
| SCHEMBL1511696 | 0.72 | F2 (0.37) | HSD11B1CCR5KMT2AF2MMP13 | |
| SCHEMBL3836513 | 0.72 | CCR5 (0.41) | HSD11B1CCR5KMT2AF2ESR2 | |
| SCHEMBL26413534 | 0.71 | CTSD (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127728-A1 | MODIFIED GRAPHENE, METHOD OF PRODUCING MODIFIED GRAPHENE, MODIFIED GRAPHENE-RESIN COMPOSITE, MODIFIED GRAPHENE SHEET, AND MODIFIED GRAPHENE DISPERSION | CANON KK (JP) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127728-A1 | MODIFIED GRAPHENE, METHOD OF PRODUCING MODIFIED GRAPHENE, MODIFIED GRAPHENE-RESIN COMPOSITE, MODIFIED GRAPHENE SHEET, AND MODIFIED GRAPHENE DISPERSION | GRIA1, GRIN1, NR3C1 | HSD11B1 403/4885CCR5 1922/4885KMT2A 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.